A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT07090499. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-label Study to Investigate PF-08046876 in Adult Participants With Advanced Solid Tumors.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to explore the safety and effects of the study drug (PF-08046876) in people diagnosed with advanced cancer of the bladder, lung, head and neck, esophagus, or pancreas. PF-08046876 is an investigational anticancer therapy called an 'antibody drug conjugate' or 'ADC'. ADCs are anticancer drugs designed to stick to cancer cells and kill them. The study drug will be given to participants through a needle in a vein (intravenous infusion). This study includes multiple parts. In the first part of the study, there will be different groups of people receiving different doses of the study drug. The study may also test different schedules.
Study identification
- NCT ID
- NCT07090499
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 540 participants
Conditions and interventions
Conditions
- Advanced/Metastatic Solid Tumors
- Bladder Cancer
- Urothelial Carcinoma
- Advanced Non-Small Cell Lung Cancer
- Carcinoma, Non Small Cell Lung
- Carcinoma, Squamous Cell of Head and Neck
- Head and Neck Cancer
- Esophageal Cancer
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Squamous Cell Carcinoma
- Esophageal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Pancreatic Cancer
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 19, 2025
- Primary completion
- Jul 7, 2028
- Completion
- Jul 7, 2029
- Last update posted
- Sep 3, 2026
2025 – 2029
United States locations
- U.S. sites
- 21
- U.S. states
- 5
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| City of Hope National Medical Center | Duarte | California | 91010 | Recruiting |
| City of Hope at Irvine Lennar | Irvine | California | 92618 | Recruiting |
| Ronald Reagan UCLA Medical Center | Los Angeles | California | 90095 | Not yet recruiting |
| UCLA Department of Medicine-Hematology/Oncology | Los Angeles | California | 90095 | Not yet recruiting |
| Santa Monica UCLA Medical Center & Orthopaedic Hospital | Santa Monica | California | 90404 | Not yet recruiting |
| UCLA Hematology/Oncology - Santa Monica | Santa Monica | California | 90404 | Not yet recruiting |
| Smilow Cancer Hospital - Yale New Haven Health | New Haven | Connecticut | 06510 | Recruiting |
| Yale - New Haven Hospital - Yale Cancer Center | New Haven | Connecticut | 06510 | Recruiting |
| Smilow Cancer Hospital Phase 1 Unit | New Haven | Connecticut | 06511 | Recruiting |
| Smilow Cancer Hospital - Trumbull | Trumbull | Connecticut | 06611 | Recruiting |
| Brigham and Women's Hospital | Boston | Massachusetts | 02115 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Dana-Farber Cancer Institute - Chestnut Hill | Newton | Massachusetts | 02467 | Recruiting |
| Sarah Cannon Research Institute - Pharmacy | Nashville | Tennessee | 37203 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas MD Anderson Cancer Center - Conroe | Conroe | Texas | 77384 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| The University of Texas, MD Anderson Cancer Center - West Houston | Houston | Texas | 77079 | Recruiting |
| The University of Texas, MD Anderson Cancer Center - League City | League City | Texas | 77573 | Recruiting |
| NEXT Oncology | San Antonio | Texas | 78229 | Recruiting |
| The University of Texas, MD Anderson Cancer Center - Sugar Land | Sugar Land | Texas | 77478 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07090499, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 3, 2026 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07090499 live on ClinicalTrials.gov.